DMP Relative Valuation - Dermapharm Holding SE

Watchlist Manager

Watchlist

Price: 36.3 EUR -0.27% Market Closed

Market Cap: €2B

Relative Value

The Relative Value of one DMP stock under the Base Case scenario is hidden EUR. Compared to the current market price of 36.3 EUR, Dermapharm Holding SE is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

What is Relative Valuation?

How is Relative Value calculated?

DMP Relative Value

Show

Worst Case

Base Case

Best Case

Valuation Multiples

View Details

Multiples Across Competitors

All Multiples

P/S

P/E

EV/EBITDA

EV/EBIT

Forward Multiples

			Market Cap	P/S	P/E	EV/EBITDA	EV/EBIT
DE		Dermapharm Holding SE XETRA:DMP	2B EUR	1.7	17.1	9.1	12.6
US		Eli Lilly and Co NYSE:LLY	997.2B USD	15.3	48.3	32.5	34.6
US		Johnson & Johnson NYSE:JNJ	578.6B USD	6.1	21.6	15	18.4
CH		Roche Holding AG SIX:ROG	281.1B CHF	4.6	30	12.7	14.8
US		Merck & Co Inc NYSE:MRK	303.5B USD	4.7	16.6	10.4	12.1
CH		Novartis AG SIX:NOVN	230.9B CHF	5.3	21.2	13.1	16.8
UK		AstraZeneca PLC LSE:AZN	216.1B GBP	5.2	32.1	15.3	22.4
IE	E	Endo International PLC LSE:0Y5F	218B USD	94	-74.6	333.1	835.4
DK		Novo Nordisk A/S CSE:NOVO B	1.3T DKK	4.2	12.7	9.3	11
US		Pfizer Inc NYSE:PFE	154.7B USD	2.5	19.9	7.4	9.9
US		Bristol-Myers Squibb Co NYSE:BMY	125.6B USD	2.6	20.8	7.3	9.6

				Revenue Growth	P/S to Growth
DE		Dermapharm Holding SE XETRA:DMP	Average P/S: 13.3 1.7	3%	0.6
US		Eli Lilly and Co NYSE:LLY	15.3	15%	1
US		Johnson & Johnson NYSE:JNJ	6.1	6%	1
CH		Roche Holding AG SIX:ROG	4.6	3%	1.5
US		Merck & Co Inc NYSE:MRK	4.7	5%	0.9
CH		Novartis AG SIX:NOVN	5.3	4%	1.3
UK		AstraZeneca PLC LSE:AZN	5.2	8%	0.6
IE	E	Endo International PLC LSE:0Y5F	94	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	4.2	7%	0.6
US		Pfizer Inc NYSE:PFE	2.5	-3%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	2.6	-3%	N/A

				Earnings Growth	PEG
DE		Dermapharm Holding SE XETRA:DMP	Average P/E: 24 17.1	9%	1.9
US		Eli Lilly and Co NYSE:LLY	48.3	28%	1.7
US		Johnson & Johnson NYSE:JNJ	21.6	7%	3.1
CH		Roche Holding AG SIX:ROG	30	29%	1
US		Merck & Co Inc NYSE:MRK	16.6	14%	1.2
CH		Novartis AG SIX:NOVN	21.2	15%	1.4
UK		AstraZeneca PLC LSE:AZN	32.1	38%	0.8
IE	E	Endo International PLC LSE:0Y5F	Negative Multiple: -74.6	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	12.7	7%	1.8
US		Pfizer Inc NYSE:PFE	19.9	26%	0.8
US		Bristol-Myers Squibb Co NYSE:BMY	20.8	N/A	N/A

				EBITDA Growth	EV/EBITDA to Growth
DE		Dermapharm Holding SE XETRA:DMP	Average EV/EBITDA: 42.3 9.1	5%	1.8
US		Eli Lilly and Co NYSE:LLY	32.5	18%	1.8
US		Johnson & Johnson NYSE:JNJ	15	2%	7.5
CH		Roche Holding AG SIX:ROG	12.7	5%	2.5
US		Merck & Co Inc NYSE:MRK	10.4	7%	1.5
CH		Novartis AG SIX:NOVN	13.1	9%	1.5
UK		AstraZeneca PLC LSE:AZN	15.3	10%	1.5
IE	E	Endo International PLC LSE:0Y5F	333.1	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	9.3	7%	1.3
US		Pfizer Inc NYSE:PFE	7.4	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	7.3	-9%	N/A

				EBIT Growth	EV/EBIT to Growth
DE		Dermapharm Holding SE XETRA:DMP	Average EV/EBIT: 90.7 12.6	5%	2.5
US		Eli Lilly and Co NYSE:LLY	34.6	17%	2
US		Johnson & Johnson NYSE:JNJ	18.4	6%	3.1
CH		Roche Holding AG SIX:ROG	14.8	6%	2.5
US		Merck & Co Inc NYSE:MRK	12.1	6%	2
CH		Novartis AG SIX:NOVN	16.8	12%	1.4
UK		AstraZeneca PLC LSE:AZN	22.4	23%	1
IE	E	Endo International PLC LSE:0Y5F	835.4	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	11	8%	1.4
US		Pfizer Inc NYSE:PFE	9.9	-1%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	9.6	10%	1

Dermapharm Holding SE
XETRA:DMP

Relative Value

Valuation Multiples

Multiples Across Competitors

DMP Competitors Multiples
Dermapharm Holding SE Competitors

See Also

Company

Help

Tools

Stocks

Dermapharm Holding SE XETRA:DMP

Relative Value

Valuation Multiples

Multiples Across Competitors

DMP Competitors Multiples Dermapharm Holding SE Competitors

See Also

Company

Help

Tools

Stocks

Dermapharm Holding SE
XETRA:DMP

DMP Competitors Multiples
Dermapharm Holding SE Competitors